Particle-by-Particle Tracking Reveals Uneven Nanoparticle Drug Release

Why It Matters

Understanding single‑particle release dynamics enables tighter control of dosing and reduces variability in patient outcomes, making nanomedicines safer and more effective.

Key Takeaways

• dSTORM tracks drug release from individual PLGA nanoparticles over 30 days
• Release rates vary widely; some particles release cargo rapidly, others retain it
• Particle swelling and count decline indicate hydration and polymer degradation
• Heterogeneous release could impact efficacy and adverse event profiles in patients
• Technique applicable to diverse nanocarriers, guiding next‑gen targeted therapies

Pulse Analysis

Nanoparticle‑based drug delivery has become a cornerstone of precision medicine, promising to ferry proteins, RNA or small‑molecule therapeutics directly to diseased tissue while shielding them from premature degradation. Commercial formulations such as PLGA‑based carriers are already approved for vaccines and cancer treatments, yet their performance is typically evaluated with bulk assays that average release kinetics across millions of particles. This averaging masks the stochastic behavior of individual nanocarriers, a factor that can translate into unpredictable dosing, sub‑therapeutic exposure, or localized toxicity once the formulation reaches patients.

In a recent paper in *Nanoscale Horizons*, researchers from the Institute of Materials Science of Barcelona combined stochastic optical reconstruction microscopy (dSTORM) with dual fluorescent labeling to monitor both the polymer matrix and encapsulated albumin on a particle‑by‑particle basis for a full month. The technique resolved release events at the nanometer scale, revealing a rapid burst in the first days followed by a prolonged, slower phase as the PLGA matrix swelled, hydrated and eventually degraded. Crucially, the data exposed a wide spectrum of release profiles: some nanoparticles emptied their cargo within hours, while others retained most of it until the polymer fully broke down.

The ability to quantify such heterogeneity reshapes how developers will design and qualify nanomedicines. By identifying outlier particles that could cause dose spikes or therapeutic gaps, formulation scientists can refine polymer composition, particle size distribution, or surface chemistry to tighten release windows. Regulators are also likely to demand more granular characterization, moving beyond bulk release curves toward single‑particle metrics. Beyond PLGA, the dSTORM workflow is adaptable to lipid nanoparticles, polymer‑drug conjugates and emerging gene‑editing carriers, positioning it as a pivotal tool for the next generation of targeted therapies.